CRTX vs. NKGN, BCLI, PLUR, SRZN, INKT, TARA, ACHL, AIM, ZIVO, and EVAX
Should you be buying Cortexyme stock or one of its competitors? The main competitors of Cortexyme include NKGen Biotech (NKGN), Brainstorm Cell Therapeutics (BCLI), Pluri (PLUR), Surrozen (SRZN), MiNK Therapeutics (INKT), Protara Therapeutics (TARA), Achilles Therapeutics (ACHL), AIM ImmunoTech (AIM), ZIVO Bioscience (ZIVO), and Evaxion Biotech A/S (EVAX). These companies are all part of the "medical" sector.
NKGen Biotech (NYSE:NKGN) and Cortexyme (NASDAQ:CRTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations, media sentiment and community ranking.
76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 63.2% of Cortexyme shares are held by institutional investors. 20.0% of NKGen Biotech shares are held by company insiders. Comparatively, 27.9% of Cortexyme shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, Cortexyme's average media sentiment score of 0.00 equaled NKGen Biotech'saverage media sentiment score.
Cortexyme received 154 more outperform votes than NKGen Biotech when rated by MarketBeat users.
NKGen Biotech has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, Cortexyme has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500.
NKGen Biotech has higher revenue and earnings than Cortexyme.
Cortexyme's return on equity of 0.00% beat NKGen Biotech's return on equity.
Summary
NKGen Biotech and Cortexyme tied by winning 4 of the 8 factors compared between the two stocks.
Get Cortexyme News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cortexyme Competitors List
Related Companies and Tools
